Ascentage Pharma Group International is a US-listed company in the biotechnology industry. Its financial year ends in December.
Loading chart…
Third-party market data · may be delayed
Under review: every model's value for Ascentage Pharma Group International is far from the share price, which usually points to a data problem (a merger, a share-count change, a one-off) rather than a bargain or a bubble.
Under review: free cash flow after stock pay is not positive. We'll show the comparison once resolved.
Ascentage Pharma Group International valuation: adjust assumptions and compare models →
What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.
Revenue for the twelve months was $80m. Free-cash-flow margin held at -209.3%. The diluted share count is up 17.9% on a year earlier, which dilutes existing holders. Against its peers on growth, profitability, cash generation and balance sheet, it grades D.
Our model value for Ascentage Pharma Group International is under review, so past values are not shown until it is resolved.
Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.
Ascentage Pharma Group International's trailing-twelve-month revenue fell 41.4% year on year, with a free-cash-flow margin of -209.3%. Where it stands out: stock pay as % of revenue of 3.6% ranks 24 of 179 biotechnology companies we cover. Where it lags: change in growth rate of -375.8pp ranks 166 of 172 biotechnology companies we cover.
Current signal Free cash flow diverging from earnings: TTM free cash flow fell 786.9% while net income fell 206.9%: a 580pp divergence.
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Loading chart…
Third-party market data · may be delayed
Company announcements, filed results and changes that matter to shareholders.
No recent updates are available for AAPG from the sources we follow. See filings →
The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.
We value Ascentage Pharma Group International as an operating company, with every model that fits that kind of business. Cost of equity 9.9%: the 10-year Treasury yield (4.9%) plus a beta of 1.1 times a 4.5% equity risk premium.
| Model | Value per share | In the combined value? |
|---|---|---|
| Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. | ~$1.0 ~$2.3–$7.9 | Left out: out of range vs price (0.08x) |
| Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. | — | Combined value withheld. Review the individual models and their assumptions. |
Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Ascentage Pharma Group International with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.
No analyst estimates are published for Ascentage Pharma Group International: too few analysts cover it.
Source: SEC EDGAR filings. Retrieved November 2, 2026.
| Period | Revenue (TTM) |
|---|---|
| FY22 Q4 | $31.2M |
| FY23 Q4 | $31.4M |
| FY24 Q4 | $136.3M |
| FY25 Q4 | $79.9M |
Source: SEC EDGAR filings. Retrieved November 2, 2026.
| Period | FCF margin (TTM) |
|---|---|
| FY22 Q4 | -408.8% |
| FY23 Q4 | -347.9% |
| FY24 Q4 | -13.8% |
| FY25 Q4 | -209.3% |
| Fiscal year | 2022 Dec 2022 | 2023 Dec 2023 | 2024 Dec 2024 | 2025 Dec 2025 |
|---|---|---|---|---|
| Income | ||||
| Revenue | 31 | 31 | 136 | 80 |
| Gross profit | 28 | 27 | 132 | 73 |
| Net income | −131 | −131 | −56 | −173 |
| Diluted EPS | −$2.00 | −$1.85 | −$0.74 | −$1.94 |
| Growth (year on year) | ||||
| Revenue | — | +0.5% | +334.5% | −41.4% |
| Margins | ||||
| Gross margin | 89.5% | 86.2% | 97.0% | 91.5% |
| Net margin | −421.0% | −417.0% | −41.3% | −216.5% |
| Free-cash-flow margin | −408.8% | −347.9% | −13.8% | −209.3% |
| Cash flow | ||||
| Cash from operations | −97 | −103 | −15 | −163 |
| Capital spending | 30 | 7 | 3 | 4 |
| Free cash flow | −128 | −109 | −19 | −167 |
| Stock-based pay | 3 | 4 | 3 | 3 |
| Free cash flow after stock pay | −131 | −114 | −22 | −170 |
| Balance sheet | ||||
| Cash | 195 | 146 | 122 | 171 |
| Total debt | 0 | 256 | 233 | 284 |
| Net debt (negative = net cash) | −195 | 109 | 110 | 113 |
| Diluted shares | 66m | 71m | 76m | 89m |
| Returned to shareholders | ||||
| Buybacks | 4 | 1 | — | 1 |
| Total returned | 4 | 1 | — | 1 |
| Last 12 months unless stated | AAPG | ADCT | PLX | BCYC | ASMB | VSTM | Median |
|---|---|---|---|---|---|---|---|
| Revenue, last 12 months | $80m | $80m | $81m | $84m | $75m | $88m | $56m |
| Revenue growth, last 12 months | −41.4% | 3.0% | 30.1% | 194.7% | 125.1% | 26.4% | 12.6% |
| Revenue growth, 3-year average | — | — | 6.1% | 49.8% | −3.3% | 58.4% | 13.7% |
| Revenue growth, latest quarter | — | 2.2% | 27.1% | 190.2% | 38.9% | >999% | 10.2% |
| Gross margin | 91.5% | — | 69.2% | — | — | — | 82.9% |
| Operating margin | — | −125.1% | 28.9% | −189.4% | −11.8% | −182.6% | −189.4% |
| Operating margin, 3-year average | — | −171.7% | 1.1% | −581.7% | −126.0% | −813.6% | −363.5% |
| Net margin | −216.5% | −121.8% | 23.5% | −169.8% | −0.1% | −231.6% | −169.8% |
| Cash from operations / revenue | −204.5% | −128.5% | 12.3% | −209.7% | −51.4% | −185.3% | −168.0% |
| Free-cash-flow margin | −209.3% | −128.5% | 9.5% | −211.9% | −51.5% | −185.3% | −162.4% |
| Free-cash-flow margin, 3-year average | — | −171.3% | −2.3% | −539.0% | −35.8% | — | −310.0% |
| Stock pay / revenue | 3.6% | 12.2% | 2.4% | 36.4% | 8.9% | 11.1% | 20.0% |
| Change in share count | 17.9% | 38.3% | −4.1% | 0.6% | 50.8% | 33.4% | 8.2% |
| Measure | Company | Peer median | Rank |
|---|---|---|---|
| Revenue growth Growth | -41.4% | 12.6% | 138 of 172 |
| Change in growth rate Growth | -375.8pp | -0.1pp | 166 of 172 |
| Gross margin Profitability | 91.5% | 82.4% | 17 of 75 |
| Net margin Profitability | -216.5% | -157.3% | 97 of 180 |
| Free-cash-flow margin Cash generation | -209.3% | -145.4% | 103 of 176 |
| Stock pay as % of revenue Cash generation | 3.6% | 19.2% | 24 of 179 |
| Change in share count Balance sheet | 17.9% | 7.9% | 113 of 156 |
| Days sales outstanding Balance sheet | 165 days | 75 days | 92 of 100 |
Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).
| Manager | Value | Shares | Share of 13F value | Shares QoQ |
|---|---|---|---|---|
| Point72 Asset Management, L.P. | $243,048 | 14K | 92.2% | ▼ 13.8% |
| Morgan Stanley | $16,138 | 1K | 6.1% | ▲ 84.5% |
| Wells Fargo & Company | $3,512 | 0K | 1.3% | New |
| Eversource Wealth Advisors, LLC | $421 | 0K | 0.2% | 0.0% |
| UBS Group AG | $263 | 0K | 0.1% | ▼ 87.9% |
| Blackrock, Inc. | $105 | 0K | 0.0% | New |
| Caitong International Asset Management Co., Ltd | $18 | 0K | 0.0% | New |
From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Ascentage Pharma Group International's complete shareholder register. Values are as reported by the filers .
From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
New research on the companies we cover arrives in the weekly email. Free, one email a week.
